KRAS and adenoma: Given that K-RAS and B-RAF wild type status is predictive of EGFR-targeted response in patents (Di Nicolantonio et al, 2008; Karapetis et al, 2008), we first determined K-ras and B-raf status in adenomas developing in the Apcmin/+ mouse.